2
|
Lee Y, Brietzke E, Cao B, Chen Y, Linnaranta O, Mansur RB, Cortes P, Kösters M, Majeed A, Tamura JK, Lui LMW, Vinberg M, Keinänen J, Kisely S, Naveed S, Barbui C, Parker G, Owolabi M, Nishi D, Lee J, Srisurapanont M, Gill H, Guo L, Balanzá-Martínez V, Partonen T, Nolen WA, Lee JH, Kim JH, Chavannes NH, Ewais T, Atienza-Carbonell B, Silven AV, Yasuma N, Gil A, Novikov A, Lacey C, Versluis A, von Malortie S, Chan LF, Waqas A, Purgato M, Aardoom JJ, Ly-Uson JT, Sim K, Tuineag M, van der Kleij RMJJ, van Luenen S, Suttajit S, Hajek T, Lee YW, Porter RJ, Alsuwaidan M, Rosenblat JD, Ravindran AV, Lam RW, McIntyre RS. Development and implementation of guidelines for the management of depression: a systematic review. Bull World Health Organ 2020; 98:683-697H. [PMID: 33177758 PMCID: PMC7652558 DOI: 10.2471/blt.20.251405] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 07/09/2020] [Accepted: 07/10/2020] [Indexed: 12/12/2022] Open
Abstract
Objective To evaluate the development and implementation of clinical practice guidelines for the management of depression globally. Methods We conducted a systematic review of existing guidelines for the management of depression in adults with major depressive or bipolar disorder. For each identified guideline, we assessed compliance with measures of guideline development quality (such as transparency in guideline development processes and funding, multidisciplinary author group composition, systematic review of comparative efficacy research) and implementation (such as quality indicators). We compared guidelines from low- and middle-income countries with those from high-income countries. Findings We identified 82 national and 13 international clinical practice guidelines from 83 countries in 27 languages. Guideline development processes and funding sources were explicitly specified in a smaller proportion of guidelines from low- and middle-income countries (8/29; 28%) relative to high-income countries (35/58; 60%). Fewer guidelines (2/29; 7%) from low- and middle-income countries, relative to high-income countries (22/58; 38%), were authored by a multidisciplinary development group. A systematic review of comparative effectiveness was conducted in 31% (9/29) of low- and middle-income country guidelines versus 71% (41/58) of high-income country guidelines. Only 10% (3/29) of low- and middle-income country and 19% (11/58) of high-income country guidelines described plans to assess quality indicators or recommendation adherence. Conclusion Globally, guideline implementation is inadequately planned, reported and measured. Narrowing disparities in the development and implementation of guidelines in low- and middle-income countries is a priority. Future guidelines should present strategies to implement recommendations and measure feasibility, cost–effectiveness and impact on health outcomes.
Collapse
Affiliation(s)
- Yena Lee
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada
| | - Elisa Brietzke
- Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada
| | - Bing Cao
- School of Psychology and Key Laboratory of Cognition and Personality, Southwest University, Chongqing, China
| | - Yan Chen
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | - Outi Linnaranta
- Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, Canada
| | - Rodrigo B Mansur
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada
| | - Paulina Cortes
- Pontificia Universidad Católica de Chile, Santiago, Región Metropolitana, Chile
| | - Markus Kösters
- Department of Psychiatry II, Ulm University, Ulm, Germany
| | - Amna Majeed
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada
| | - Jocelyn K Tamura
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada
| | - Leanna M W Lui
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada
| | - Maj Vinberg
- Psychiatric Research Unit, Psychiatric Centre North Zealand, Hilleroed, University Hospital of Copenhagen, Copenhagen, Denmark
| | - Jaakko Keinänen
- Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland
| | - Steve Kisely
- School of Clinical Medicine, The University of Queensland, Brisbane, Australia
| | - Sadiq Naveed
- Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas, USA
| | - Corrado Barbui
- WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Biomedicine and Movement Sciences, Verona, Italy
| | - Gary Parker
- Global Alliance for Chronic Diseases, Wellcome Trust, London, England
| | - Mayowa Owolabi
- Center for Genomics and Precision Medicine, University of Ibadan, Ibadan, Nigeria
| | - Daisuke Nishi
- Department of Mental Health, The University of Tokyo, Tokyo, Japan
| | - JungGoo Lee
- Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea
| | | | - Hartej Gill
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada
| | - Lan Guo
- School of Public Health, Sun Yat-sen University, Guangdong, China
| | - Vicent Balanzá-Martínez
- Teaching Unit of Psychiatry and Psychological Medicine, University of Valencia, Valencia, CIBERSAM, Spain
| | - Timo Partonen
- Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland
| | - Willem A Nolen
- Department of Psychiatry, University of Groningen, Groningen, Netherlands
| | - Jae-Hon Lee
- Department of Psychiatry, Gyeongsang National University Hospital, Jinju, Republic of Korea
| | - Ji Hwan Kim
- Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea
| | - Niels H Chavannes
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
| | - Tatjana Ewais
- School of Clinical Medicine, The University of Queensland, Brisbane, Australia
| | | | - Anna V Silven
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
| | - Naonori Yasuma
- Department of Mental Health, The University of Tokyo, Tokyo, Japan
| | - Artyom Gil
- WHO European Office for the Prevention and Control of Noncommunicable Diseases, Division of Country Health Programme, Moscow, Russian Federation
| | - Andrey Novikov
- Psychiatric and Neurological Hospital, Surgut, Russian Federation
| | - Cameron Lacey
- Maori Indigenous Health Institute, University of Otago, Christchurch, New Zealand
| | - Anke Versluis
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
| | | | - Lai Fong Chan
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Department of Psychiatry, Queen's University School of Medicine, Kingston, Canada
| | - Ahmed Waqas
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,School of Psychology and Key Laboratory of Cognition and Personality, Southwest University, Chongqing, China
| | - Marianna Purgato
- WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Biomedicine and Movement Sciences, Verona, Italy
| | - Jiska Joëlle Aardoom
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
| | - Josefina T Ly-Uson
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | - Kang Sim
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, Canada
| | - Maria Tuineag
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Pontificia Universidad Católica de Chile, Santiago, Región Metropolitana, Chile
| | | | - Sanne van Luenen
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
| | - Sirijit Suttajit
- Department of Psychiatry, Chiang Mai University, Chiang Mai, Thailand
| | - Tomas Hajek
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Department of Psychiatry II, Ulm University, Ulm, Germany
| | - Yu Wei Lee
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, Canada
| | - Richard J Porter
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Psychiatric Research Unit, Psychiatric Centre North Zealand, Hilleroed, University Hospital of Copenhagen, Copenhagen, Denmark
| | - Mohammad Alsuwaidan
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland
| | - Joshua D Rosenblat
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,School of Clinical Medicine, The University of Queensland, Brisbane, Australia
| | - Arun V Ravindran
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,School of Clinical Medicine, The University of Queensland, Brisbane, Australia
| | - Raymond W Lam
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada.,Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas, USA
| | - Roger S McIntyre
- Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, 399 Bathurst St 9MP-325, Toronto, Ontario, Canada
| | | |
Collapse
|